Samsung Biologics Publishes 2023 ESG Report
Report reiterates CDMO’s commitment to net-zero emissions.
Samsung Biologics, a contract development and manufacturing organization (CDMO), released its 2023 environmental, social, and governance (ESG) report. The annual report outlines the company’s progress toward meeting its sustainability goals, along with the strategies to accomplish its social responsibilities and create long-term value for stakeholders.
Highlights of the report include:
Establishing a net-zero pathway: As part of the company’s mission to deliver net zero by 2050 or earlier, Samsung Biologics established new milestones: to cut 32% of direct emissions by 2030 and 62% by 2040, while reducing 36% of suppliers’ emissions by 2030 and 73% by 2040. Last year, the company also committed to 100% renewable power through the RE100 initiative.
Implementing responsible business practices: Samsung Biologics joined the United Nations Global Compact, a global corporate sustainability initiative, to demonstrate its commitment to sustainable business practices, as well as to implement the initiative’s 10 principles addressing human rights, labor standards, the environment, and anti-corruption.
“Samsung Biologics is fully committed to engaging in sustainable business practices for the positive impact it has on our clients, society, and the wider community,” notes John Rim, president and CEO of Samsung Biologics. “We will continue to leverage our expertise and experience to accelerate the delivery of net-zero healthcare, and engage with our suppliers and partners to amplify our collective efforts.”
